Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia

Kidu Gidey; Abadi Mache; Berhane Yohannes Hailu; Solomon Weldegebreal Asgedom; Segen Gebremeskel Tassew; Yirga Legesse Nirayo

doi:10.2147/IDR.S419348

Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia

Infect Drug Resist. 2023 Jul 27:16:4903-4912. doi: 10.2147/IDR.S419348. eCollection 2023.

Authors

Kidu Gidey¹, Abadi Mache¹, Berhane Yohannes Hailu¹, Solomon Weldegebreal Asgedom¹, Segen Gebremeskel Tassew¹, Yirga Legesse Nirayo¹

Affiliation

¹ Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.

Abstract

Introduction: Ethiopia has one of the highest HIV burdens in sub-Saharan Africa. Despite the fact that second-line antiretroviral therapy (ART) has been available for more than ten years, studies on its effectiveness are scarce.

Objective: To assess treatment outcomes and predictors of unfavorable outcomes in HIV patients receiving second-line ART at Ayder Comprehensive Specialized Hospital and Mekelle Hospital.

Materials and methods: An institution-based retrospective cohort study was conducted in two hospitals in Tigray Region, Ethiopia. We evaluated 192 patients aged ≥15 years who were switched to second-line from November 2009 to May 2020 after failure of first-line ART. The primary outcome was the time from the initiation of second-line ART to the occurrence of unfavorable treatment outcomes (treatment failure, death, and loss to follow-up). We performed Kaplan-Meier survival estimates to calculate the cumulative incidence rates of unfavorable outcomes.

Results: The mean age (SD) at the initiation of second-line ART was 39 (10.03) years, and the median CD4 cell count was 121 cells/microL. During a median follow-up of 4.6 years, 24 (12.5%) patients had died, 11 (5.7%) patients were lost to follow up, and 47 (24,4%) patients were experienced treatment failure. The incidence rates for unfavorable outcomes were 7.8 per 100 patients/years. Predictors for unfavorable outcomes were body mass index (BMI) <18.5 (adjusted hazard ratio [aHR] = 2.51, 95% confidence interval (CI): 1.27-4.95) and CD4 counts ≤100 cells/microL (aHR = 1.74, 95% CI: 1.09-2.79). Despite the failure of second-line ART, none of the patients received third-line ART.

Conclusion: The incidence rate of unfavorable treatment outcomes for second-line ART was found to be high. A low BMI and a low baseline CD4 count were significant predictors of unfavourable outcomes and should be given special consideration in HIV care. A third-line ART regimen should also be considered for people who have failed second-line ART.

Keywords: human immunodeficiency virus; outcomes; second-line ART.

Grants and funding

The study was carried out as part of our routine work.